Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Milrinone, sold under the brand name Primacor among others, is a pulmonary vasodilator used in patients who have heart failure. It is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility and decrease pulmonary vascular resistance. Milrinone also works to vasodilate which helps alleviate increased pressures (afterload) on the heart, thus improving its pumping action. While it has been used in people with heart failure for many years, studies suggest that milrinone may exhibit some negative side effects that have caused some debate about its use clinically.
Read the full article on Wikipedia“Milrinone is a phosphodiesterase-3 inhibitor. It inhibits the action of phosphodiesterase-3 and thus prevents degradation of cyclic adenosine monophosphate (cAMP). Normally, cyclic adenosine monophosphate causes increased activation of protein kinase A (PKA). Protein kinase A is an enzyme that phosphorylates many elements of the contractile machinery within the heart cell. In the short term this leads to an increased force of contraction. Phosphodiesterases are enzymes responsible for the breakdown of cyclic adenosine monophosphate. Therefore, when phosphodiesterases lower the level of cyclic adenosine monophosphate in the cell they also lower the active fraction of protein kinase A within the cell and reduce the force of contraction.”
“2.3 hours (mean, in CHF)”
Working under the parallel aged-care framework? Aged-care equivalent →